EBAG9/RCAS1 expression in hepatocellular carcinoma: Correlation with tumour dedifferentiation and proliferation

European Journal of Cancer

Volumn 39, Issue 11, 2003, Pages 1552-1561

  Aoki, T ^a   Inoue, S ^a   Imamura, H ^a   Fukushima, J ^c   Takahashi, S ^b   Urano, T ^a   Hasegawa, K ^a   Ogushi, T ^b   Ouchi, Y ^a   Makuuchi, M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EBAG9 RCAS1; Hepatocellular carcinoma; Immunohistochemistry; Ki 67 labelling index; Tumour dedifferentiation; Tumour proliferation; Western blotting analysis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PROPERTY; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

EID: 0037478980     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00362-9     Document Type: Article

References (34)

1. Watanabe T., Inoue S., Hiroi H., Orimo A., Kawashima H., Muramatsu M. Isolation of estrogen-responsive genes with a CpG island library. Mol. Cell Biol. 18:1998;442-449.
2. Tsuchiya F., Ikeda K., Tsutsumi O.et al. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen. expression and regulation by estrogen Biochem. Biophys. Res. Commun. 284:2001;2-10.
3. Suzuki T., Inoue S., Kawabata W.et al. EBAG9/RCAS1 in human breast carcinoma. a possible factor in endocrine-immune interactions Br. J. Cancer. 85:2001;1731-1737.
4. Sonoda K., Nakashima M., Kaku T., Kamura T., Nakano H., Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer. 77:1996;1501-1509.
5. Nakashima M., Sonoda K., Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat. Med. 5:1995;938-942.
6. Sonoda K., Kaku T., Kamura T., Nakashima M., Watanabe T., Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin. Cancer Res. 4:1998;1517-1520.
7. Iwasaki T., Nakashima M., Watanabe T.et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int. J. Cancer. 89:2002;488-493.
8. Izumi M., Nakanishi Y., Yoshino I., Nakashima M., Watanabe T., Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer. 82:2001;446-451.
9. Takahashi H., Iizuka H., Nakashima M.et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. J. Dermatol. Sci. 26:2001;140-144.
10. Kubokawa M., Nakashima M., Yao T.et al. Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int. J. Oncol. 19:2001;695-700.
11. Oshikiri T., Hida Y., Miyamoto M.et al. RCAS1 as a tumour progression marker. an independent negative prognostic factor in gallbladder cancer Br. J. Cancer. 85:2001;1922-1927.
12. Nakakubo Y., Hida Y., Miyamoto M.et al. The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett. 177:2002;101-105.
13. Suzuoki M., Hida Y., Miyamoto M.et al. RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma. Ann. Surg. Oncol. 9:2002;388-393.
14. Enjoji M., Nakashima M., Nishi H.et al. The tumor-associated antigen, RCAS1 can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract. J. Hepatol. 36:2000;786-792.
15. Hiraoka K., Hida Y., Miyamoto M.et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int. J. Cancer. 99:2002;418-423.
16. Noguchi K., Enjoji M., Nakamuta M.et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett. 158:2001;197-202.
17. Kojiro M., Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis. 19:1999;287-296.
18. Takayama T., Makuuchi M., Hirohashi S.et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 28:1998;1241-1246.
19. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 4th edn. 2000;Kanehara & Co. Ltd, Tokyo. pp. 28-34.
20. Ng I.O.L., Na J., Lai E.C.S., Fan S.T., Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. a comparison with proliferating cell nuclear antigen Am. J. Clin. Pathol. 104:1995;313-318.
21. Ito Y., Matsuura N., Sakon M.et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br. J. Cancer. 81:1999;747-751.
22. Nakamura S., Suzuki S., Sakaguchi T.et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer. 78:1996;1671-1676.
23. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
24. Pugh R.N.H., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60:1973;646-649.
25. Kosuge T., Makuuchi M., Takayama T., Yamamoto J., Shimada K., Yamasaki S. Long-term results after resection of hepatocellular carcinoma. experience of 480 cases Hepato-gastroenterol. 40:1993;328-332.
26. Cox D., Oakes D. Analysis of Survival Data. 1983;Chapman and Hall, London.
27. Sonoda K., Kaku T., Hirakawa T.et al. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol. Oncol. 79:2000;424-429.
28. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1984;1710-1715.
29. Cher M.L., Chew K., Rosenau W., Carroll P.R. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate. 26:1995;87-93.
30. Goodson III W.H., Moore II D.H., Ljung B.M.et al. The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer. Breast Cancer Res. Treat. 49:1998;155-164.
31. Scholzen T., Gerdes J. The Ki-67 protein. from the known and the unknown J. Cell. Physiol. 182:2000;311-322.
32. Okabe H., Satoh S., Kato T.et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray. identification of genes involved in viral carcinogenesis and tumor progression Cancer Res. 61:2001;2129-2137.
33. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 74:1994;2772-2780.
34. Yamamto J., Kosuge T., Takayama T.et al. Recurrence of hepatocellular carcinoma after surgery. Br. J. Surg. 83:1996;1219-1222.